Last Chance! Join Us in One Week – Spots Still Open

There is less than one week left to make plans to attend our 2025 Annual Educational Meeting, Monday, October 27th, at the Hilton Garden Inn, just minutes from the Detroit Metro Airport in Detroit, Michigan. Make your travel plans and register for the meeting today! Discounted registration of only $49 per person is still available.

This event is in-person only and is a great opportunity to meet with and learn from others affected by mefloquine. Visit our registration page for details on accommodations and travel and for a full meeting agenda.

Lariam Lawsuit Gets New Life on Appeal

As reported recently in the Stars and Stripes, the Ninth U.S. Circuit Court of Appeals has partially reversed a 2024 ruling that had dismissed the complaints of four mefloquine veterans. After hearing arguments in the matter of Caston, et al. v. Hoffmann-La Roche, Inc., et al., the appeals court ruled that the precedent set by Marbury v. Madison does not bar plaintiffs from proceeding in suing Genentech, the company that purchased Roche, the original manufacturer of Lariam.

The suit is being brought by veterans Andrea Caston, Richard Githens, Patrick Wagher, and Kendrick Allen, who filed the original lawsuit in 2023 on behalf of themselves and other service members. The plaintiffs are represented by Kozyak Tropin & Throckmorton, LLP.

U.K. Ministry of Defence Confirms Settlement of 434 Lariam Cases

The U.K. Ministry of Defence has now confirmed settlement of 434 Lariam cases. As previously reported, although the terms of the settlement are subject to a gag order, the reported total settlement is £20 million, or approximately $27 million.

Quinism Foundation’s Dr. Nevin on the Operation Tango Romeo Podcast

Dr. Remington Nevin, executive and medical director of The Quinism Foundation, recently appeared on the Operation Tango Romeo Podcast with host Mark Meincke.

Dr. Nevin and Mark discussed a wide range of topic, including challenges in the diagnosis and treatment of quinism, the refusal of governments to recognize the condition, its confounding by PTSD and TBI, and the history of mefloquine and related antimalarial drugs.